{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:26:31Z","timestamp":1790389591795,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Vancomycin-resistant enterococci (VRE) account for a large proportion of hospital-acquired infections. Determining optimal treatment of VRE urinary tract infections (UTIs) is challenging. The purpose of this study was to determine if a difference in efficacy or safety exists between linezolid and non-linezolid treatments for VRE UTIs. This retrospective cohort evaluated patients admitted between 1 June 2012\u201330 November 2017 who were treated for VRE UTI. Patients must have had at least one sign, symptom, or laboratory confirmation of UTI to be included. The primary endpoint of this study was difference in clinical cure between linezolid and non-linezolid treatment options. Secondary endpoints included 30-day recurrence, 30-day infection-related readmission, inpatient mortality, infection-related hospital length of stay (LOS), and time to appropriate therapy. A total of 45 patients (33 linezolid and 12 non-linezolid) were included. Clinical cure occurred in 71.4% linezolid and 58.3% non-linezolid (p = 0.476). No patients had a 30-day infection-related readmission or 30-day recurrence. Of the 45 patients, 6 (13.3%) patients died during admission, and 5 of those deaths were in the linezolid group (p = 1.000). No significant difference was found for clinical cure between linezolid and non-linezolid treatment options for VRE UTIs.<\/jats:p>","DOI":"10.3390\/pharmacy9040175","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T23:55:23Z","timestamp":1635292523000},"page":"175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2037-2616","authenticated-orcid":false,"given":"Mary Joyce","family":"Wingler","sequence":"first","affiliation":[{"name":"Department of Antimicrobial Stewardship, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Baptist Health Care, 1000 W Morena St, Pensacola, FL 32501, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0952-3321","authenticated-orcid":false,"given":"S. Travis","family":"King","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ochsner Medical Center, 1514 Jefferson Hwy, New Orleans, LA 70121, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-7894","authenticated-orcid":false,"given":"Jamie L.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-3111","authenticated-orcid":false,"given":"Katie E.","family":"Barber","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-0137","authenticated-orcid":false,"given":"Kayla R.","family":"Stover","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Mississippi School of Pharmacy, 2500 North State Street, Jackson, MS 39216, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":"NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006\u20132007","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17658","DOI":"10.1038\/s41598-020-74834-y","article-title":"Increasing relevance of Gram-positive cocci in urinary tract infections: A 10-year analysis of their prevalence and resistance trends","volume":"10","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"570650","DOI":"10.3389\/fpubh.2021.570650","article-title":"Linezolid resistance in Enterococcus faecalis associated with urinary tract infections of patients in a tertiary hospitals in China: Resistance mechanisms, virulence, and risk factors","volume":"9","author":"Ma","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Isac, R., Basaca, D.-G., Olariu, I.-C., Stroescu, R., Ardelean, A.-M., Steflea, R., Gafencu, M., Chirita-Emandi, A., Bagiu, I., and Horhat, F. (2021). Antibiotic resistance patterns of uropathogens causing urinary tract infections in children with congenital anomalies of kidney and urinary tract. Children, 8.","DOI":"10.3390\/children8070585"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.2147\/IDR.S311229","article-title":"Catheter-associated urinary tract infection: Incidence, associated factors and drug resistance patterns of bacterial isolates in southern Ethiopia","volume":"14","author":"Kuwa","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.52547\/rbmb.10.1.50","article-title":"Prevalence of virulence genes and antibiotic resistance pattern in Enterococcus faecalis isolated from urinary tract infection in Shahrekord, Iran","volume":"10","author":"Tajbakhsh","year":"2021","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/AAC.00455-10","article-title":"Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm","volume":"54","author":"Vidaillac","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S54125","article-title":"Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management","volume":"8","author":"Crank","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4065\/81.4.529","article-title":"Vancomycin-resistant enterococci: Colonization, infection, detection, and treatment","volume":"81","author":"Zirakzadeh","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1592\/phco.30.11.1136","article-title":"Vancomycin-resistant enterococcal urinary tract infections","volume":"30","author":"Heintz","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4111\/icu.2016.57.2.129","article-title":"Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom","volume":"57","author":"Toner","year":"2016","journal-title":"Investig. Clin. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14787210.2.1.51","article-title":"A review of linezolid: The first oxazolidinone antibiotic","volume":"2","author":"Stevens","year":"2004","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.47.12.3789-3794.2003","article-title":"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose","volume":"47","author":"Wagenlehner","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1093\/ofid\/ofu052.753","article-title":"Linezolid compared to daptomycin for the treatment of vancomycin-resistant enterococcal urinary tract infections","volume":"1","author":"Moenster","year":"2014","journal-title":"Open Form Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2050312120970743","DOI":"10.1177\/2050312120970743","article-title":"Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus","volume":"8","author":"Pontefract","year":"2020","journal-title":"SAGE Open Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1345\/aph.1R604","article-title":"Serotonergic and adrenergic drug interactions associated with linezolid: A critical review and practical management approach","volume":"47","author":"Ramsey","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/1060028018783498","article-title":"Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater","volume":"52","author":"Rabon","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.diagmicrobio.2006.12.022","article-title":"Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: A report from the SENTRY antimicrobial surveillance program","volume":"58","author":"Deshpande","year":"2007","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/IPC.0000000000000193","article-title":"Empiric and targeted treatment of enterococcal infections: Opportunities for antimicrobial stewardship","volume":"23","author":"Taimur","year":"2015","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijantimicag.2017.06.008","article-title":"Ampicillin for the treatment of complicated urinary tract infections caused by vancomycin-resistant Enterococcus spp (VRE): A single-center university hospital experience","volume":"51","author":"Shah","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1128\/AAC.01817-15","article-title":"Outcomes of aminopenicillin therapy for vancomycin-resistant enterococcal urinary tract infections","volume":"59","author":"Cole","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","unstructured":"Agency for Healthcare Research and Quality (2018, October 16). Preventing CAUTI: Focus on Culturing Stewardship, Available online: http:\/\/www.ahrq.gov\/professionals\/quality-patient-safety\/hais\/cauti-tools\/phys-championsgd\/section7.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ofid\/ofw172.259","article-title":"Urine culture stewardship as a component of urinary catheter infection prevention in five intensive care units","volume":"1","author":"Campbell","year":"2016","journal-title":"Open Forum Infect. Dis."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/9\/4\/175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:24:06Z","timestamp":1760167446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/9\/4\/175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmacy9040175"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy9040175","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}